- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 12, 2022
Highlights
- Market Cap
- $984.05M
- Enterprise Value
- $882.27M
- EPS (TTM)
- -$0.35
- EBITDA (TTM)
- -$576.72M
- Year Range
- $0.11 - $1.67
- ROA (TTM)
- -202.02%
- ROE (TTM)
- 5.67%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ZVSA Performance Chart
ZyVersa Therapeutics Inc. (ZVSA) is up 23.5% since the beginning of the year. At $0 per share, ZVSA is trading 90.1% below its 52-week high of $2.
Loading charts...
Returns By Period
ZyVersa Therapeutics Inc. (ZVSA) has returned 23.50% so far this year and -74.46% over the past 12 months.
ZyVersa Therapeutics Inc.
- 1D
- -12.70%
- 1M
- -8.33%
- YTD
- 23.50%
- 6M
- 23.50%
- 1Y
- -74.46%
- 3Y*
- -87.81%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ZVSA Monthly Returns History
Based on dividend-adjusted daily data since Dec 12, 2022, ZVSA's average daily return is -0.51%, while the average monthly return is -13.51%.
Historically, 26% of months were positive and 74% were negative. The best month was Feb 2024 with a return of +93.0%, while the worst month was Dec 2022 at -84.3%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 11 months.
On a daily basis, ZVSA closed higher 38% of trading days. The best single day was Dec 12, 2022 with a return of +125.0%, while the worst single day was Apr 26, 2023 at -69.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.76% | 62.50% | -23.08% | 5.35% | -2.80% | -19.43% | 23.50% | ||||||
| 2025 | 31.13% | -18.71% | -44.37% | -2.97% | 2.87% | 7.92% | -70.63% | -42.07% | 27.60% | -7.48% | 1.10% | -2.84% | -87.40% |
| 2024 | -36.66% | 92.95% | -31.82% | -29.47% | -6.62% | -23.89% | -7.98% | -20.23% | -13.04% | -16.25% | -46.57% | -1.30% | -88.22% |
| 2023 | 17.20% | 19.59% | -12.29% | -75.93% | -21.21% | -32.92% | -29.74% | -17.57% | -8.93% | -36.53% | -20.92% | -60.44% | -98.36% |
| 2022 | -84.30% | -84.30% |
Benchmark Metrics
ZyVersa Therapeutics Inc. has an annualized alpha of -74.29%, beta of 0.36, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 12, 2022.
- This stock participated in 366.77% of S&P 500 Index downside but only -169.97% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.36 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -74.29%
- Beta
- 0.36
- R²
- 0.00
- Upside Capture
- -169.97%
- Downside Capture
- 366.77%
Return for Risk
Risk / Return Rank
ZVSA ranks 21 for risk / return — below 21% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ZyVersa Therapeutics Inc. (ZVSA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZVSA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.51 | ||
| Sortino ratioReturn per unit of downside risk | -2.94 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.37 | -0.39 |
| Calmar ratioReturn relative to maximum drawdown | -0.88 | 2.78 | -3.66 |
| Martin ratioReturn relative to average drawdown | -1.00 | 12.44 | -13.44 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ZyVersa Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ZyVersa Therapeutics Inc. was 100.00%, occurring on Aug 29, 2025. The portfolio has not yet recovered.
The current ZyVersa Therapeutics Inc. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -100.00%Aug 2025 | 2y 8mo | — | 3y 6moDec 2022 - now |
Drawdown Indicators
| ZVSA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -85.14% | -9.10% | -76.04% |
Max Drawdown (3Y)Largest decline over 3 years | -99.88% | -18.90% | -80.98% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -1.80% | -98.20% |
Average DrawdownAverage peak-to-trough decline | -98.70% | -10.71% | -87.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 74.62% | 2.03% | +72.59% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ZyVersa Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ZyVersa Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ZVSA
Add ZyVersa Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ZVSA